AVXL / Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease

Anavex Life Sciences Corp. presented follow-on data from its Alzheimer's disease trial. This data uses a statistical methodology that is difficult to more_horizontal

Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET more_horizontal

Not much has happened at Anavex Life Sciences Corp. since my last coverage in March. There are a few pieces of news, which I cover here. The toplining more_horizontal

Anavex Life Sciences (NASDAQ:AVXL) Corp announced earlier this week that its Rett syndrome treatment showed a disease-modifying effect in a long-term more_horizontal

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmac more_horizontal

Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year. more_horizontal

Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's disease. If granted more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectivenes more_horizontal